Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Newamsterdam Pharma B V (Dutch Chamber Of Commerce No 5597 1946) has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being handled by 1 distinct examiner within 1 distinct art unit. The prosecution activity is currently limited to this single matter, which is typical for companies focusing on a specific pharmaceutical candidate or a niche biotechnological process. This focused approach ensures that the company's intellectual property efforts are concentrated on a high-priority asset within 1 distinct art unit.
AFUA BAMFOAA BOATENG is the busiest examiner for the portfolio, holding 1 busiest examiner pending office action. This examiner is responsible for the company's entire active workload, as the total count of 1 pending office action is limited. The alignment of 1 distinct examiner and the action indicates a specific focus for the company's current patent office interactions. This structure means that the company's immediate success in the patent office is tied to the examination of this application by this specific professional.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOATENG, AFUA BAMFOAA | 1 | 46.7% | +64.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18725746 | Obicetrapib and SGLT2 Inhibitor Combination | BOATENG, AFUA BAMFOAA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18725746 | Obicetrapib and SGLT2 Inhibitor Combination | BOATENG, AFUA BAMFOAA | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18725746 | Obicetrapib and SGLT2 Inhibitor Combination | BOATENG, AFUA BAMFOAA | 1617 | §103§112 | Non-Final OA | — | Pending | Jun 28, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNewamsterdam Pharma B V (Dutch Chamber Of Commerce No 5597 1946) has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Afua Bamfoaa Boateng has the most, with 1 of Newamsterdam Pharma B V (Dutch Chamber Of Commerce No 5597 1946)'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
